FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined With Immune Checkpoint Inhibition — FusionVAC22  

Fibrolamellar Hepatocellular Carcinoma Clinical Trial

Official title: FusionVAC22_01: DNAJB1-PRKACA Fusion Transcript-based Peptide Vaccine Combined With Immune Checkpoint Inhibition for Fibrolamellar Hepatocellular Carcinoma and Other Tumor Entities Carrying the Oncogenic Driver Fusion

Status Recruiting

Clinical Trial Summary

The aim of this clinical trial is to evaluate the immunogenicity along with safety and toxicity as well as first efficacy of a DNAJB1-PRKACA fusion transcript-based peptide vaccine (Fusion-VAC-XS15) in combination with anti-programmed cell death-ligand 1 immune checkpoint inhibition (ICI) by Atezolizumab (TecentriqTM) in patients with Fibrolamellar hepatocellular carcinoma (FL-HCC) or other cancer entities carrying the DNAJB1-PRKACA fusion transcript.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Fibrolamellar Hepatocellular Carcinoma

• NCT number: NCT05937295
• Study type: Interventional
• Source: University Hospital Tuebingen
• Contact: Juliane Walz, Prof. Dr.
• Phone: +49(0)707129
• Email: kketi@med.uni-tuebingen.de
• Status: Recruiting
• Phase: Phase 1
• Start date: September 26, 2023
• Completion date: January 2027